Thrombosis Research
Volume 125, Issue 3 , Pages 210-215 , March 2010

Factor XII: What does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis

  • Evi Stavrou
    • ,
  • Alvin H. Schmaier

      Affiliations

    • Corresponding Author InformationCorresponding author. Case Western Reserve University, 10900 Euclid Avenue, WRB 2-130, Cleveland, OH 44106-7284, USA. Tel.: +1 216 368 1172; fax: +1 216 368 3014.

Received 21 November 2009 ,Revised 21 November 2009 ,Accepted 23 November 2009.

References 

  1. Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest. Apr 1955;34(4):602–613
  2. Davie EW, Ratnoff OD. Waterfall Sequence for Intrinsic Blood Clotting. Science. Sep 18 1964;145:1310–1312
  3. Ghebrehiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med. Mar 1 1981;153(3):665–676
  4. Citarella F, Tripodi M, Fantoni A, Bernardi F, Romeo G, Rocchi M. Assignment of human coagulation factor XII (fXII) to chromosome 5 by cDNA hybridization to DNA from somatic cell hybrids. Hum Genet. Dec 1988;80(4):397–398
  5. Cool DE, MacGillivray RT. Characterization of the human blood coagulation factor XII gene. Intron/exon gene organization and analysis of the 5'-flanking region. J Biol Chem. Oct 5 1987;262(28):13662–13673
  6. Petersen TE, Thogersen HC, Skorstengaard K, Vibe-Pedersen K, Sahl P, Sottrup-Jensen L, et al. Partial primary structure of bovine plasma fibronectin: three types of internal homology. Proc Natl Acad Sci U S A. Jan 1983;80(1):137–141
  7. Yamada KM. Cell surface interactions with extracellular materials. Annu Rev Biochem. 1983;52:761–799
  8. Clarke BJ, Cote HC, Cool DE, Clark-Lewis I, Saito H, Pixley RA, et al. Mapping of a putative surface-binding site of human coagulation factor XII. J Biol Chem. Jul 5 1989;264(19):11497–11502
  9. Samuel M, Samuel E, Villanueva GB. Histidine residues are essential for the surface binding and autoactivation of human coagulation factor XII. Biochem Biophys Res Commun. Feb 26 1993;191(1):110–117
  10. Pixley RA, Stumpo LG, Birkmeyer K, Silver L, Colman RW. A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation. J Biol Chem. Jul 25 1987;262(21):10140–10145
  11. Citarella F, Ravon DM, Pascucci B, Felici A, Fantoni A, Hack CE. Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. Eur J Biochem. May 15 1996;238(1):240–249
  12. Citarella F, Fedele G, Roem D, Fantoni A, Hack CE. The second exon-encoded factor XII region is involved in the interaction of factor XII with factor XI and does not contribute to the binding site for negatively charged surfaces. Blood. Dec 1 1998;92(11):4198–4206
  13. Baglia FA, Jameson BA, Walsh PN. Identification and characterization of a binding site for factor XIIa in the Apple 4 domain of coagulation factor XI. J Biol Chem. Feb 25 1993;268(6):3838–3844
  14. Mahdi F, Madar ZS, Figueroa CD, Schmaier AH. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood. May 15 2002;99(10):3585–3596
  15. Henderson LM, Figueroa CD, Muller-Esterl W, Bhoola KD. Assembly of contact-phase factors on the surface of the human neutrophil membrane. Blood. Jul 15 1994;84(2):474–482
  16. Bradford HN, Pixley RA, Colman RW. Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation. J Biol Chem. Jul 28 2000;275(30):22756–22763
  17. Hasan AA, Zisman T, Schmaier AH. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci U S A. Mar 31 1998;95(7):3615–3620
  18. Mahdi F, Shariat-Madar Z, Todd RF, Figueroa CD, Schmaier AH. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood. Apr 15 2001;97(8):2342–2350
  19. Rojkaer R, Schousboe I. Partial identification of the Zn2+-binding sites in factor XII and its activation derivatives. Eur J Biochem. Jul 15 1997;247(2):491–496
  20. Cool DE, Edgell CJ, Louie GV, Zoller MJ, Brayer GD, MacGillivray RT. Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa. J Biol Chem. Nov 5 1985;260(25):13666–13676
  21. Cohen S. Epidermal growth factor. In Vitro Cell Dev Biol. Apr 1987;23(4):239–246
  22. Chien P, Pixley RA, Stumpo LG, Colman RW, Schreiber AD. Modulation of the human monocyte binding site for monomeric immunoglobulin G by activated Hageman factor. J Clin Invest. Nov 1988;82(5):1554–1559
  23. Gordon EM, Venkatesan N, Salazar R, Tang H, Schmeidler-Sapiro K, Buckley S, et al. Factor XII-induced mitogenesis is mediated via a distinct signal transduction pathway that activates a mitogen-activated protein kinase. Proc Natl Acad Sci U S A. Mar 5 1996;93(5):2174–2179
  24. Schmeidler-Sapiro KT, Ratnoff OD, Gordon EM. Mitogenic effects of coagulation factor XII and factor XIIa on HepG2 cells. Proc Natl Acad Sci U S A. May 15 1991;88(10):4382–4385
  25. Fernando AN, Fernando LP, Fukuda Y, Kaplan AP. Assembly, activation, and signaling by kinin-forming proteins on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. Jul 2005;289(1):H251–H257
  26. Citarella F, te Velthuis H, Helmer-Citterich M, Hack CE. Identification of a putative binding site for negatively charged surfaces in the fibronectin type II domain of human factor XII–an immunochemical and homology modeling approach. Thromb Haemost. Dec 2000;84(6):1057–1065
  27. Revak SD, Cochrane CG, Griffin JH. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest. Jun 1977;59(6):1167–1175
  28. Fujikawa K, McMullen BA. Amino acid sequence of human beta-factor XIIa. J Biol Chem. Sep 25 1983;258(18):10924–10933
  29. Dunn JT, Silverberg M, Kaplan AP. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem. Feb 25 1982;257(4):1779–1784
  30. Rojkjaer R, Hasan AA, Motta G, Schousboe I, Schmaier AH. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost. Jul 1998;80(1):74–81
  31. Wiggins RC, Cochrane CC. The autoactivation of rabbit Hageman factor. J Exp Med. Nov 1 1979;150(5):1122–1133
  32. Samuel M, Pixley RA, Villanueva MA, Colman RW, Villanueva GB. Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. J Biol Chem. Sep 25 1992;267(27):19691–19697
  33. Chen X, Wang J, Paszti Z, Wang F, Schrauben JN, Tarabara VV, et al. Ordered adsorption of coagulation factor XII on negatively charged polymer surfaces probed by sum frequency generation vibrational spectroscopy. Anal Bioanal Chem. May 2007;388(1):65–72
  34. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. Jun 5 2008;358(23):2457–2467
  35. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A. Apr 10 2007;104(15):6388–6393
  36. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A. Jan 24 2006;103(4):903–908
  37. Maas C, Govers-Riemslag JW, Bouma B, Schiks B, Hazenberg BP, Lokhorst HM, et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest. Sep 2008;118(9):3208–3218
  38. van der Meijden PE, Munnix IC, Auger JM, Govers-Riemslag JW, Cosemans JM, Kuijpers MJ, et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood. Jul 23 2009;114(4):881–890
  39. Matsumoto K, Yamamoto T, Kamata R, Maeda H. Pathogenesis of serratial infection: activation of the Hageman factor-prekallikrein cascade by serratial protease. J Biochem. Sep 1984;96(3):739–749
  40. Kaminishi H, Hamatake H, Cho T, Tamaki T, Suenaga N, Fujii T, et al. Activation of blood clotting factors by microbial proteinases. FEMS Microbiol Lett. Sep 1 1994;121(3):327–332
  41. Forbes CD, Pensky J, Ratnoff OD. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J Lab Clin Med. Nov 1970;76(5):809–815
  42. Pixley RA, Schmaier A, Colman RW. Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor. Arch Biochem Biophys. Aug 1 1987;256(2):490–498
  43. Stead N, Kaplan AP, Rosenberg RD. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem. 1976 Nov 10;251(21):6481–6488
  44. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002 Apr;109(8):1057–1063
  45. Cichon S, Martin L, Hennies HC, Muller F, Van Driessche K, Karpushova A, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet. 2006 Dec;79(6):1098–1104
  46. Farsetti A, Misiti S, Citarella F, Felici A, Andreoli M, Fantoni A, et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology. 1995 Nov;136(11):5076–5083
  47. Farsetti A, Moretti F, Narducci M, Misiti S, Nanni S, Andreoli M, et al. Orphan receptor hepatocyte nuclear factor-4 antagonizes estrogen receptor alpha-mediated induction of human coagulation factor XII gene. Endocrinology. 1998 Nov;139(11):4581–4589
  48. Inoue Y, Peters LL, Yim SH, Inoue J, Gonzalez FJ. Role of hepatocyte nuclear factor 4alpha in control of blood coagulation factor gene expression. J Mol Med. Apr 2006;84(4):334–344
  49. Spronk H, Heemskerk JW, Ten Cate H, Knetch ML, Gailani D, Pawlinski R, et al. Feedback activation of factor XI by thombin is essential for haemostasis in vivo. J Thromb Haemost. 2009;7(s2):1–316
  50. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol. Sep 1961;36:212–219
  51. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. Jul 18 2005;202(2):271–281
  52. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. Mar 20 2006;203(3):513–518
  53. Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost. Sep 7 1992;68(3):285–290
  54. Koster T, Rosendaal FR, Briet E, Vandenbroucke JP. John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia Study. Br J Haematol. Jun 1994;87(2):422–424
  55. Santamaria A, Mateo J, Tirado I, Oliver A, Belvis R, Marti-Fabregas J, et al. Homozygosity of the T allele of the 46 C->T polymorphism in the F12 gene is a risk factor for ischemic stroke in the Spanish population. Stroke. Aug 2004;35(8):1795–1799
  56. Soria JM, Almasy L, Souto JC, Bacq D, Buil A, Faure A, et al. A quantitative-trait locus in the human factor XII gene influences both plasma factor XII levels and susceptibility to thrombotic disease. Am J Hum Genet. Mar 2002;70(3):567–574
  57. Zito F, Lowe GD, Rumley A, McMahon AD, Humphries SE. Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis. Nov 2002;165(1):153–158
  58. Endler G, Mannhalter C, Sunder-Plassmann H, Lalouschek W, Kapiotis S, Exner M, et al. Homozygosity for the C–>T polymorphism at nucleotide 46 in the 5' untranslated region of the factor XII gene protects from development of acute coronary syndrome. Br J Haematol. Dec 2001;115(4):1007–1009
  59. Colhoun HM, Zito F, Norman Chan N, Rubens MB, Fuller JH, Humphries SE. Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis. Aug 2002;163(2):363–369
  60. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood. Dec 15 2006;108(13):4045–4051
  61. Gailani D, Renne T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease?. J Thromb Haemost. Jun 2007;5(6):1106–1112
  62. Sabater-Lleal M, Chillon M, Mordillo C, Martinez A, Gil E, Mateo J, et al. Combined cis-regulator elements as important mechanism affecting FXII plasma levels. Thromb Res. Sep 26 2009;
  63. Sladek FM, Ruse MD, Nepomuceno L, Huang SM, Stallcup MR. Modulation of transcriptional activation and coactivator interaction by a splicing variation in the F domain of nuclear receptor hepatocyte nuclear factor 4alpha1. Mol Cell Biol. Oct 1999;19(10):6509–6522
  64. McMullen BA, Fujikawa K. Amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Hageman factor). J Biol Chem. May 10 1985;260(9):5328–5341
  65. Schousboe I. Contact activation in human plasma is triggered by zinc ion modulation of factor XII (Hageman factor). Blood Coagul Fibrinolysis. Oct 1993;4(5):671–678
  66. Ravon DM, Citarella F, Lubbers YT, Pascucci B, Hack CE. Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein. Blood. Dec 1 1995;86(11):4134–4143

PII: S0049-3848(09)00541-6

doi: 10.1016/j.thromres.2009.11.028

Thrombosis Research
Volume 125, Issue 3 , Pages 210-215 , March 2010

Article Tools

* Image Usage & Resolution